Demcizumab, referred to as OMP 21M18 and assigned the CAS registry number 1243262-17-0, is a novel monoclonal antibody targeting selectively inhibiting a function of angiopoietin- receptor- 2. Research demonstrate its https://janacapt178192.wikiexpression.com/user